131 related articles for article (PubMed ID: 36512647)
1. Matrix Metalloproteinases 2 and 9 and Their Tissue Inhibitors in the Diagnostics of Medullary Thyroid Carcinoma.
Vázquez-Lorente H; Dunđerović DM; Tatić SB; Radojević-Škodrić S; Gomes CM; Paunović IR; Dragutinović V
Appl Immunohistochem Mol Morphol; 2023 Feb; 31(2):121-127. PubMed ID: 36512647
[TBL] [Abstract][Full Text] [Related]
2. Relationship between Trace Elements and Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in Medullary Thyroid Carcinoma.
Vázquez-Lorente H; Dundjerović DM; Tatić SB; Rodríguez-Menéndez S; González-Iglesias H; Gomes CM; Paunović IR; Dragutinović VV
Biol Trace Elem Res; 2023 Jul; 201(7):3225-3232. PubMed ID: 36156766
[TBL] [Abstract][Full Text] [Related]
3. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications.
Cavalheiro BG; Junqueira CR; Brandão LG
Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826
[TBL] [Abstract][Full Text] [Related]
5. False-positive staining of thyroglobulin distinguished from mixed medullary and follicular thyroid carcinoma by duplex in situ hybridization.
Takeshima K; Ariyasu H; Uraki S; Morita S; Furukawa Y; Inaba H; Iwakura H; Doi A; Warigaya K; Murata SI; Enomoto K; Hotomi M; Akamizu T
Endocr J; 2020 Oct; 67(10):1007-1017. PubMed ID: 32522910
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas.
Tomita T
Histopathology; 1997 Aug; 31(2):150-6. PubMed ID: 9279566
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
8. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the amyloid associated with human medullary thyroid carcinoma.
Khurana R; Agarwal A; Bajpai VK; Verma N; Sharma AK; Gupta RP; Madhusudan KP
Endocrinology; 2004 Dec; 145(12):5465-70. PubMed ID: 15459123
[TBL] [Abstract][Full Text] [Related]
10. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
11. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.
Seok JY; Kang M; De Peralta-Venturina M; Fan X
Int J Surg Pathol; 2021 Sep; 29(6):615-626. PubMed ID: 33650906
[TBL] [Abstract][Full Text] [Related]
14. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
16. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer.
Kartal Baykan E; Erdoğan M
Turk J Med Sci; 2021 Apr; 51(2):650-656. PubMed ID: 33128357
[TBL] [Abstract][Full Text] [Related]
17. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
19. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
20. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
